Navigation Links
Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
Date:11/1/2011

PRINCETON, N.J., Nov. 1, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype or their ability to take interferon therapy.

"After recent discussions with Health Authorities, we are excited to be initiating the first of a series of pivotal studies to explore an interferon-free regimen of PSI-7977 in broad populations of individuals with HCV," said Michael Rogers, Ph.D., Pharmasset's Chief Development Officer.

The first trial, FISSION, will enroll approximately 500 treatment-naive patients with HCV genotype 2 or 3, and will evaluate the safety and efficacy of a 12-week interferon-free regimen of PSI-7977 and ribavirin compared to 24 weeks of pegylated interferon and ribavirin. The primary endpoint of the study is sustained virologic response 12 weeks after the completion of treatment (SVR12).

Pharmasset plans to initiate a second 12-week duration, interferon-free Phase 3 trial, POSITRON, in early 2012. This trial will enroll approximately 225 patients with HCV genotype 2 or 3 who cannot take interferon.

In mid-2012, Pharmasset intends to initiate a third 12-week duration, interferon-free Phase 3 trial, NEUTRINO. This trial will enroll patients who cannot take interferon, and will include patients with HCV regardless of viral genotype, including those with HCV genotype 1. The final study design will be based on emerging data from ELECTRON and from PSI-7977 plus RBV-containing arms in the ongoing QUANTUM study.

"Based on encouraging results to date, we have selected an IFN-free regimen of PSI-7977/RBV for our registrational program," said Michelle Berrey, MD, MPH, Pharmasset's Chief
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015  Rigrodsky & Long, P.A.: , Do you, ... AERI )? , Did you purchase your shares between ... you lose money in your investment in Aerie Pharmaceuticals, Inc.? ... Rigrodsky & Long, P.A. , including former Special Assistant ... complaint has been filed in the United States District Court for ...
(Date:5/6/2015)... STOCKHOLM and PRETORIA, South Africa ... Africa , cancer kills more people than HIV/AIDS, malaria ... be prevented[2] and 40 percent can be cured with the ... a dozen African nations are working to build up their ... 50 percent of all cancer patients worldwide would benefit from ...
(Date:5/6/2015)... , May 06, 2015 Research and Markets ... "Energy based Ablation Devices - Global Strategic Business Report" ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , and Rest of World. ... through 2020. Also, a seven-year historic analysis is provided for ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 3Elekta to bring cancer treatment to millions in Africa 2Elekta to bring cancer treatment to millions in Africa 3Elekta to bring cancer treatment to millions in Africa 4Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 2Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 3
... LigoCyte Pharmaceuticals,Inc., today announced a strategic partnership ... targeting CD103 for the treatment of chronic,inflammatory ... CD103 is the unique alphaE-beta7 integrin that,has ... retention of lymphocytes,that mediate inflammatory diseases affecting ...
... be webcast live at http://www.wilsoncenter.org/globalhealth , WASHINGTON, ... called for a reauthorization of the President,s,Emergency Plan for ... the end,of fiscal year 2008. The plan calls for ... $15 billion to $30 billion over the next five,years., ...
Cached Medicine Technology:Director's Forum: PEPFAR and the Global AIDS Response 2
(Date:5/6/2015)... Mass. (PRWEB) May 06, 2015 ... today announced that CTO David Ting will lead a ... the associated data security and user authentication challenges, during ... Fla.). The session will focus on the benefits of ... in which care providers and patients can share information. ...
(Date:5/6/2015)... A quality built chicken coop condo with a ... way to raise chickens on a pasture. By installing a ... will have a chicken tractor that stands up to being moved ... as it is able to flex to uneven ground without losing ... land are fertilized, and it will help provide the chickens with ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Corporate ... behalf of MEBC, an Alliance Award for excellence ... during FOCUS 2015, JDA’s annual user conference which ... retail and wholesale distribution sectors. This award recognizes ... are receiving services that advance their supply chain ...
(Date:5/6/2015)... Vancouver, BC (PRWEB) May 06, 2015 ... colon hydrotherapy supplier, is excited to announce a ... will help reduce the industry’s carbon footprint while ... These kits feature Eco-Flex™, the world’s ... “This is a game-changer for hydrotherapists,” claims the ...
(Date:5/6/2015)... King of Prussia, PA (PRWEB) May 06, 2015 ... Business Process Outsourcing solutions to the Medicare Advantage, Medicare ... three finalists in the Continuity and Resilience Team category ... by the Business Continuity Institute to recognize the outstanding ... or operating in the North America Region, including the ...
Breaking Medicine News(10 mins):Health News:Imprivata to Lead Discussion about Patient and Provider Authentication Challenges and the Internet of Things in Healthcare during Citrix Synergy 2Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3
... shows a laugh signifies more than humor and ridicule, ... // of the role of laughter during psychotherapy. ... than about humor. Researchers videotaped therapeutic sessions and took ... where patients were being treated for outpatient mood and ...
... weight loss surgery should probably be tested to see ... disorders, say researchers according to findings of a recent ... and has also been linked to stomach cancer. However ... people undergoing gastric bypass surgery a weight loss operation ...
... 60 are affected by Parkinson’s disease. The condition is characterized ... from loss of facial rigidity // and a shuffling walk. ... of Parkinson’s disease may also be able to stop its ... found to completely halt the neurotoxic effects of a chemical ...
... increase ones risk for breast cancer. A recent study ... for one year experienced a two-fold increase in breast ... risk of having an abnormal mammogram was four-times greater, ... ages 50 and 79. The average woman was 62 ...
... the risk of developing liver cancer and more than ... researchers based on findings of a recent study. ... with 12 different types of cancer to 509 healthy ... of diabetes were more likely to be diagnosed with ...
... of alcohol may increase the risk of developing an ... men and women. Participants were given questionnaires that assessed ... they consumed. It was found that men consumed an ... while the women consumed about 14 grams. ,During ...
Cached Medicine News:
Designed for rapid, routine electrophoresis for nucleic acids. The Mini unit is designed with a choice of two casting systems: standard casting trays that require sealing tape; or aluminum-gated cast...
... Wide mini horizontal gel system is designed for very ... agarose gels. This System allows the user to cast, ... quality. Complete system with : 1 x electrophoresis tank ... MT-T01 (105 x 83 mm tray), 2 x MT-T02 ...
... Hoefer offers the HE 33 Mini Submarine Unit for ... HE 33 is designed for very fast separations of ... base acts as a heat-sink. Fill the base with ... run, by either keeping the unit in a freezer ...
... The SEA 2000 Electrophoresis Apparatus (patented) ... your DNA and RNA electrophoresis., In combination ... SEA 2000 covers applications that require a ... bed system., With the SEA 2000 it ...
Medicine Products: